Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 39 % of short-term debt in 2025; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 73.9 to 54.2.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
miDiagnostics from Leuven, company number BE0641984602, closed financial year 2025 with a result of € -12.6 million after tax. For that financial year miDiagnostics recorded revenue of € 24,934 and equity of € -10.6 million. Compared with financial year 2024, the result moved from € -18.6 million to € -12.6 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 24, 2026.
€ -10.6 million
▼ € 12.6 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -12.6 million
▲ 32 % less loss than in 2024
Profit after tax over the fiscal year.
€ 652,998
▼ 93% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -12.6 million.
People and assets in 2025
54.2
▼ 14.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 5.6 million
▼ 13% vs 2024
€ 103,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 99,854
▼ 7% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 18.5 million
▲ 16% vs 2024
Loans from banks and other lenders, long and short.
€ 2.6 million
▲ 18% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 66 days on average.
€ 841,351
▼ 46% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 252,716 | € 6,629 | € 14,467 | € 24,934 | ▲ 72% |
| Profit after taxes | € -27,526,312 | € -23,616,802 | € -18,572,530 | € -12,595,117 | ▲ € 6 million |
| Equity | € 14,063,728 | € 566,927 | € 1,994,397 | € -10,600,721 | ▼ € 12.6 million |
| Total debts | € 16,426,135 | € 24,763,295 | € 25,186,053 | € 22,204,084 | ▼ 12% |
| Cash | € 3,749,372 | € 536,620 | € 8,872,121 | € 652,998 | ▼ 93% |
| Retained profit | € -45,229,541 | € -23,616,802 | € -18,572,530 | € -12,595,117 | ▲ € 6 million |
| Bank debt | € 11,103,313 | € 19,025,221 | € 16,000,000 | € 18,500,000 | ▲ 16% |
| Balance sheet total | € 30,489,863 | € 25,330,221 | € 27,180,449 | € 11,603,363 | ▼ 57% |
| Employees (FTE) | 92.8 | 73.9 | 68.6 | 54.2 | ▼ 14.4 |
Key figures of miDiagnostics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to miDiagnostics?
What happened at miDiagnostics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Pamica NV stepped down as director. NBB
- Van den Bruinhorst Management Consultancy BV stepped down as director. NBB
- BEVER Consulting BV stepped down as director. NBB
- Peter Verhaeghe stepped down as director. NBB
- DR. IR. U. Vandeurzen Management Firm NV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 12.6 million. Source: NBB ↗
- Pamica NV became a director. NBB
- Van den Bruinhorst Management Consultancy BV became a director. NBB
In short
From € 27.5 million loss in 2022 to € 12.6 million loss in 2025.
Pays suppliers within 66 days on average.
A new publication or filing at miDiagnostics? We notify you, reason included.
Follow miDiagnosticsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Alychlo NV (31.8%), VF Capital (22.4%), Pamica NV (12.4%), Fidimec NV (6.9%), Thermo Fisher Diagnostics (6.5%) and Participatiemaatschappij Vlaanderen (6.4%).
Directors
According to the 2025 annual accounts
Director · represented by Akkermans Michel Gustaaf
Also active at: Interuniversitair Micro-Electronica Centrum, APPROACH BELGIUM, IntellectEU, YIELDS, Ceeyu, MONITR, Curewiki, IMEC International +4 more
since 2024 · until 2030
Van den Bruinhorst Management Consultancy BV
Director · represented by Willem Van Den Bruinhorst
since 2024 · until 2030
Director · represented by Els Degroote
Also active at: Smartphoto group, WEDIM, ENSO HOSPITALITY, LEDAP, AS2, Triginta, ATCARS, OTRA Solutions +10 more
since 2024 · until 2030
Peter Verhaeghe
Director
Also active at: Bedrijvencentrum De Eiken, Domein van Vorselaar, Participatiemaatschappij Vlaanderen, Peter Verhaeghe, HARAN, Orgues De Facto, TOOLS & DIES MANAGEMENT SERVICES
since 2024 · until 2030
DR. IR. U. Vandeurzen Management Firm NV
Director · represented by Urbanus Vandeurzen
Owns 22.4% via VF Capital
Also active at: DI LEGNO INTERIORS, DLI Invest, Fund+, ALDEA CONSTRUCT, HARMONEY, Smile Invest, Smile Invest Management Company, Triginta +5 more
since 2024 · until 2030
Shareholders
31.8%
VF Capital · holding of DR. IR. U. Vandeurzen Management Firm NV
22.4%
12.4%
6.9%
Thermo Fisher Diagnostics
6.5%
6.1%
Johns Hopkins University
1.4%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 1
3001 Leuven
Vaartdijk 59 box 2
3018 Leuven
Active since 1 March 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →reMYND
€ -217,249 gross margin · 2025
DName-iT
€ -71,430 gross margin · 2025
ALIGOS BELGIUM
€ 3.2 million gross margin · 2025
Pledge Therapeutics
€ -97,474 gross margin · 2024
PALEO
€ 1.5 million gross margin · 2025
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
GODADDY-SXB, DE
Domain
Domain
midiagnostics.com
Registered
2014-07-17
Registrar
Combell NV
Expires
2026-07-17
Website info
Features
Security
Details
- Company number
- 0641.984.602
- VAT number
- BE 0641.984.602
- Registered office
- Gaston Geenslaan 1, 3001 Leuven
- Names & denominations
- miDiagnostics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 October 2015
- Peppol
- Active · Active since 21 Oct 2025
- Contact
- midiagnostics.com
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied